Amarin chief executive Joseph Zakrzewski said the company had reduced staff levels by half as announced in the aftermath of its failure to secure support from a Food and Drug Administration (FDA) advisory panel for its proposal to expand its target market. Photograph: Cyril Byrne /The Irish Times

Future prospects for Irish biopharma group Amarin are uncertain after it raised doubts last night about its ability to fund a key trial to extend the (...)

Irish biopharma group Amarin booked wider losses in the second quarter of the year, despite revenues of $5.5 million from its new cholesterol-lowering(...)